DUBLIN, Jan. 18, 2024 /PRNewswire/ — The “2023 U.S. Vaccine Market Report” report has been added to ResearchAndMarkets.com’s offering.
The U.S. vaccine market is valued at $23.8 billion in 2023 and is projected to increase by 47% to $35.1 billion in 2030. The growth of the vaccine market is driven largely by the commercialization of the COVID-19 vaccine and the development of new innovative vaccines.
Overall vaccination coverage among adults and children has decreased in recent years as vaccine hesitancy and fatigue have risen. The 2023 Vaccine Market Report describes the overall vaccine market, including the approval process, updated vaccination schedules, vaccines progressing through clinical trials, necessary vaccine supplies, and market value for childhood, adult, influenza, and COVID-19 vaccines.
Key Findings
Doses administered: Over 676 million doses of the individual COVID-19 vaccine and booster doses were administered in the U.S. by May of 2023.
Vaccination rates: Adult vaccination rates in 2022 declined 14% compared to 2019.
Doses manufactured: An estimated 170 million doses of the influenza vaccine will be manufactured for the 2023-2024 flu season, a 17% decrease from the prior flu season.
Key Topics Covered:
Executive Summary
Vaccine Market Overview
Vaccine Categories And Development Platforms
Messenger RNA Vaccines Evolve To Target Infectious Disease Prevention And Cancer Treatment
Plasmid DNA Breast Cancer Vaccine Shows Promise In Early-Phase Studies
FDA Approves First Vaccine Designed To Prevent RSV Disease In Infants, Babies, And Toddlers
Routine Childhood Vaccination Rates Remain Below Key Targets
Rising Vaccine Hesitancy Is Impacting Vaccine Coverage
Combined COVID-Flu Combination Vaccine No Longer Expected In 2023
Updated Vaccines Are Authorized And Recommended For 2023-2024 COVID-19 Season
Global COVID-19 Vaccine Market Experiences Drop In Projected Sales
Pharmacies Play A Key Role In COVID-19 Vaccine Administration For Adults And Children
CDC Adds COVID-19 Vaccine To Adult And Child Immunization Schedules
Minimal Updates To Flu Vaccine Composition Ahead Of The 2023-2024 Flu Season
Influenza Activity And Market Value Rise As Manufacturing Falls
High Australian Flu Cases Precede U.S. Flu Season
Pediatric And Adolescent Vaccination Schedule Grows
HPV Vaccination Rate Among Adolescents Continues To Fall Behind Other Vaccines
Initial Study Demonstrates Efficacy And Safety Of Needle-Free Measles-Rubella Vaccine
Limited Number Of Domestic Manufacturers Contributes To Vaccine Supply Chain Disruptions
Government Programs Or Insurance Cover Most Recommended Vaccines
Appendices
For more information about this report visit https://www.researchandmarkets.com/r/c9r6b9
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
